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Protein S-nitrosation (SNO-protein), the nitric oxide-mediated posttrans-
lational modification of cysteine thiols, is an important regulatory
mechanism of protein function in both physiological and pathological
pathways. A key first step toward elucidating the mechanism by which
S-nitrosation modulates a protein’s function is identification of the tar-
geted cysteine residues. Here, we present a strategy for the simulta-
neous identification of SNO-cysteine sites and their cognate proteins to
profile the brain of the CK-p25–inducible mouse model of Alzheimer’s
disease-like neurodegeneration. The approach—SNOTRAP (SNO trap-
ping by triaryl phosphine)—is a direct tagging strategy that uses phos-
phine-based chemical probes, allowing enrichment of SNO-peptides
and their identification by liquid chromatography tandem mass spec-
trometry. SNOTRAP identified 313 endogenous SNO-sites in 251 pro-
teins in the mouse brain, of which 135 SNO-proteins were detected
only during neurodegeneration. S-nitrosation in the brain shows re-
gional differences and becomes elevated during early stages of neuro-
degeneration in the CK-p25 mouse. The SNO-proteome during early
neurodegeneration identified increased S-nitrosation of proteins impor-
tant for synapse function, metabolism, and Alzheimer’s disease pathol-
ogy. In the latter case, proteins related to amyloid precursor protein
processing and secretion are S-nitrosated, correlating with increased
amyloid formation. Sequence analysis of SNO-cysteine sites identified
potential linear motifs that are altered under pathological conditions.
Collectively, SNOTRAP is a direct tagging tool for global elucidation
of the SNO-proteome, providing functional insights of endoge-
nous SNO proteins in the brain and its dysregulation during
neurodegeneration.
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Protein S-nitrosation (SNO-protein), in which a cysteine (Cys)thiol is converted to a nitrosothiol (RSNO), is an important
posttranslational modification (PTM). Cys residues targeted for
S-nitrosation often impact enzyme activity, protein localization,
and protein–protein interactions (1). SNO begins with the pro-
duction of nitric oxide radicals (NO•) via conversion of L-argi-
nine to L-citrulline by nitric oxide synthase 1 (NOS1) (neuronal),
NOS2 (inducible), and NOS3 (endothelial). NO-mediated SNO
PTMs are thought to occur in vivo predominantly through
radical recombination between NO• and a thiyl radical,
transnitrosation by low-molecular weight NO carriers such as
S-nitrosoglutathione (GSNO), or protein-assisted transnitrosation
(2–8). In the healthy brain, low levels of NO and normal SNO
PTMs play important roles in regulating synaptic plasticity, gene
expression, and neuronal survival. In contrast, elevated NO levels
associated with aging and environmental stress have been linked
to neurological pathologies, including Alzheimer’s (AD), Parkin-
son’s, and Huntington’s disease (9). AD is the most prevalent form
of human dementia, with a frequency that progressively increases
in aging societies (10). A pivotal role in development and pro-
gression of late-onset AD, and other age-dependent dementias,
has been attributed to inflammatory and oxidative stress cascades
in the brain (11, 12), which are potentiated by elevated levels of
nitrosating and oxidizing species (13, 14).
Despite the biological importance of this PTM, significant
gaps exist regarding its in vivo specificity and origin. Character-
ization of endogenous proteins suggests that not all reduced Cys
residues on a given protein and not all Cys-containing proteins
are S-nitrosated, implying a biased selection. Although S-nitro-
sation has been frequently reported, the specific SNO residues
for many of the proteins have not been determined and can be
critical for determining their function. Currently, the identifica-
tion of a specific SNO residue involves an iterative combination
of mutagenic and mass spectrometry (MS)-based approaches. The
prototypical method for detecting SNO-proteins is the biotin-
switch technique (BST), which requires blocking of all free Cys-
thiols, followed by selective ascorbate reduction of SNO-Cys
residues that are biotinylated and isolated for analysis (9, 15–17).
One limitation of the BST is that false positives can occur
through incomplete blocking of free Cys-thiols, making them
difficult to distinguish from true SNO-Cys residues. The vari-
ability of the BST and similar methods has driven a search for
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alternative approaches for accurate SNO-Cys detection and
mapping.
In this context, we have developed a method that enables
global, facile, and high-throughput identification of endogenous
SNO-Cys residues. SNOTRAP (SNO trapping by triaryl phos-
phine) is a direct tagging technique that allows enrichment and
identification of SNO-proteins and their cognate SNO-sites.
Hyperactivation of cyclin-dependent kinase-5 (Cdk5) by its acti-
vator peptide, p25, leads to AD-like neurodegenerative pathology,
and inhibition of p25 activity ameliorates AD phenotypes (18–20).
The CK-p25 mouse model of AD-like neurodegeneration allows
temporal characterization of neurodegeneration through inducible
expression of the p25 activator peptide, leading to elevated amy-
loid-β levels and DNA damage, followed by synaptic loss, neuronal
death, and cognitive impairments (21–24). SNOTRAP was used
here to profile changes in the SNO-proteome of the CK-p25
mouse model of AD-like neurodegeneration and healthy con-
trols (21, 22). Our data provide insights into signaling pathways
that may be perturbed by SNO in the neurodegenerating brain
that could provide novel avenues for AD-related therapies.
Results and Discussion
Site-Specific Identification of SNO-Peptides. SNOTRAP is a proteo-
mic extension of the method described earlier for detecting low-
molecular–weight RSNOs using phosphine ester reagents (25).
The SNOTRAP probe consists of a triphenylphosphine thioester
linked to a biotin molecule through a polyethyleneglycol (PEG)
spacer group. The method is based on reaction of the triphenyl-
phosphine thioester with RSNO and subsequent biotin-mediated
affinity capture of labeled peptides and/or proteins. The probe
reacts with SNO groups, first yielding an azaylide intermediate,
which through a properly positioned electrophile (thioester), rear-
ranges to form a disulfide–iminophosphorane (Fig. S1A) (25, 26).
The reaction proceeds through a Staudinger ligation-type mecha-
nism that retains the nitrogen atom and thiol moiety, allowing
unequivocal confirmation of specific SNO-sites in the peptide.
Overall, the workflow consists of three main steps: (i) blocking of
reduced Cys residues with iodoacetamide (IAM), (ii) capture and
release of SNO-proteins or SNO-peptides, and (iii) nanoflow liq-
uid chromatography (nLC)–MS/MS analysis (Fig. 1A). Blocking
with IAM prevents transnitrosation during sample preparation,
ensuring that the in vivo location of SNO-sites is retained.
To identify SNO proteins, and their cognate SNO-sites, we used
two complementary approaches (Fig. 1A). The first was to identify
SNO proteins, whereby SNOTRAP-modified proteins were
enriched by streptavidin affinity (Fig. 1A, approach A). Tryptic
peptides were analyzed by LC–MS/MS, and proteins were iden-
tified by database searching. Identification of SNO-sites using
approach A was hindered due to extra features in the mass spectra
arising from the SNOTRAP tag. These features include (i) limited
ionization due to the added bulkiness of the triphenylphosphine–
PEG–biotin (SNOTRAP) tag, (ii) added features to the collision-
induced dissociation (CID) spectra such as tag-related fragment
ions and corresponding neutral losses, and (iii) ion suppression
by the dominant ions created by the SNOTRAP tag.
Consequently, a second approach (B) was developed that
substitutes N-ethyl maleimide (NEM) for the bulky SNOTRAP
tag, which allows direct detection of SNO-sites by MS. Briefly,
proteolytic digestion is performed before streptavidin capture to
isolate modified peptide fragments that contain the SNOTRAP
tag rather than intact SNO-proteins. (Fig. 1A, approach B). The
SNOTRAP tag is subsequently cleaved, the peptides eluted with
triscarboxyethylphosphine (TCEP), and the liberated Cys labeled
with NEM before nLC–MS/MS. This strategy selectively en-
riches only SNO-containing peptides, which reduces the com-
plexity of the nLC separation and improves the detection of
SNO-sites. The diagnostic fragment ions (DFIs) at m/z 126.0550,
125.0477, and 158.0276 verify that this was a SNO-peptide
(Fig. 1B and Fig. S1B) (27, 28). Our criteria for identification
of SNO-proteins required detection of two or more tryptic
peptides per SNO-protein using approach A and the SNO-Cys
site-specific peptide identification using approach B.
Cortical tissues from CK-p25 mice were analyzed independently
by capture of SNO-proteins (approach A) and SNO-peptides (ap-
proach B), using multiple biological replicates. Proteins were
identified by Spectrum Mill (Agilent) for both approaches and
pooled for analysis. By matching peptides for a given protein using a
combination of both approaches, we identified 251 proteins
(Dataset S1). DFIs in MS/MS spectra using approach B pin-
pointed 313 SNO-sites within these proteins (Dataset S1; MS/MS
spectra can be viewed at web.mit.edu/toxms/www/SNOTRAP/).
Detection of SNO-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) on Cys-150, as previously reported by others using
independent approaches, validated the robustness of the protocol
(Fig. S1 B and C) (16, 29). SNOTRAP also detected previously
unidentified SNO-sites, such as SNO-Cys284 of gephyrin (GPHN1),
indicating the sensitivity of the method (Fig. S1 B and C). The
SNOTRAP approach was able to detect and identify a large number
of endogenous SNO-proteins and SNO-sites in the brain and is
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Fig. 1. Site-specific identification of SNO-protein. (A) Schematic for selective la-
beling and analysis of SNO-proteins. Unmodified Cys-thiols were blocked,
and SNO-Cys sites were labeled with the b-SNOTRAP probe. For approach A,
b-SNOTRAP–tagged proteins were enriched using streptavidin beads, washed,
eluted with denaturing conditions, trypsin-digested, and analyzed by LC–MS/MS.
For approach B, the proteome was trypsin-digested, and b-SNOTRAP–tagged
peptides were enriched using streptavidin beads, followed by release of
the biotin linker by TCEP; alkylated with NEM; and analyzed by LC–MS/MS.
(B) Generation of DFIs from NEM-modified peptides.
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complementary to previous reports for mouse, rat, and human (Fig.
S1F) (16, 30–32).
To control for false positives that may result from nonspecific
interactions with the streptavidin beads, pretreatment with TCEP,
UV, and ascorbate-Cu were used to displace SNO PTMs before
reaction with the SNOTRAP probe and analyzed by MS (Fig.
S1D). Samples pretreated with TCEP were also analyzed by
Western blot (Fig. S1E). Approximately 3% of peptides and 5% of
proteins (Materials and Methods) were identified as false positives
(present in both the test samples and negative controls) and were
removed from further analysis.
SNO-Proteins Identified During Early Neurodegeneration. To de-
termine temporal changes during neurodegeneration of SNO-
proteins and their cognate SNO-Cys sites, we used the CK-p25
mouse model of AD-like neurodegeneration. CK-p25 mice show
early signs of neurodegeneration, including DNA damage, in-
creased amyloid-β, and the onset of neuroinflammation, before
behavior abnormalities (Fig. 2A) (21, 22, 33). After 6 wk of p25
induction, mice exhibit learning and memory impairments and
signs of advanced neurodegeneration, such as neuronal death
and reduced synapse number (23, 24). To assess changes in SNO
in the brain during the progression of neurodegeneration, we
first measured GSNO levels in the hippocampus, cortex, and
cerebellum of CK-p25 mice and p25 control littermates during
early (2 wk) and later (6 wk) stages of neurodegeneration. In
control mice, the levels of GSNO were highest in the cerebellum,
reflecting previous observations that NOS1 expression is high in
the cerebellum of adult mice (13). During early stages of neu-
rodegeneration, GSNO increased in the cortex and the hippo-
campus to levels (twofold and threefold, respectively) that either
resembled or surpassed that of the cerebellum (Fig. 2B). In-
creased SNO levels in 2-wk–induced CK-p25 mice correlate with
elevated DNA damage previously observed in these regions (24).
In the cerebellum, no increase in GSNO was observed at 2 wk,
which likely reflects the low level of p25 induction in this brain
region (21). GSNO levels in the hippocampus and cortex during
a later stage of neurodegeneration return to levels similar to
controls. Low levels of NO lead to S-nitrosation, whereas high
levels cause cell death (14). The reduction of GSNO levels at a
later stage of neurodegeneration could reflect a change in the
proportion of cell types in these regions, including a loss of
neurons and gliosis (21), although the possibility of lowered SNO
production cannot be excluded. Collectively, our results suggest
that elevated GSNO in the hippocampus and cortex is an early
indicator of neurodegeneration and that elevated SNO may be a
driving mechanism for disease progression.
To assess the endogenous SNO-proteome profile in the brains
of CK-p25 and control mice during early stages of neuro-
degeneration (2 wk), SNO-proteins were isolated and identified
in the cortex, hippocampus, and cerebellum. We detected a
larger number of SNO-proteins and SNO-sites in CK-p25 mice
compared with controls. In control mice, 152 SNO-sites and 116
SNO-proteins were identified, compared with 292 SNO-sites and
237 SNO-proteins in the CK-p25 mice (Dataset S1). The largest
increase in CK-p25–specific SNO-proteins was detected in the
cortex (Fig. 2C), which is consistent with elevated levels of GSNO
during early neurodegeneration (Fig. 2B). Of the 212 SNO-proteins
identified in the cortex, almost two-thirds (64%) were detected only
in the CK-p25 mice (Fig. 2C and Dataset S1). A total of 264 SNO-
Cys sites were identified in the cortex, of which 160 (61%) were
found exclusively in CK-p25 mice (Dataset S1).
We detected 89 SNO-proteins in the hippocampus. Although
AD pathology is readily observed in the hippocampus and our
data show elevated GSNO, the majority of detected SNO-proteins
(70%) were common between CK-p25 and controls (Fig. 2C). The
reduced number of proteins may reflect a limitation in the total
protein we obtained from the hippocampus (Fig. 2C and Dataset
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Fig. 2. Altered levels of SNO are detected in CK-p25 mice during early
stages of neurodegeneration. (A) Timeline of the pathological progression
of the CK-p25 mouse model of neurodegeneration. (B) GSNO concentration
(μM) in the cortex, hippocampus, and cerebellum of control or CK-p25 mice
following induction of p25 expression for 2 wk or 6 wk. Two-way ANOVA;
Dunnett’s multiple comparisons; ****P < 0.0001, ***P < 0.001, *P < 0.05;
n = 4 for 2-wk samples and n = 3 for 6-wk samples; mean ± SEM. (C) Number
of SNO-proteins identified in the cortex, hippocampus, and cerebellum of
control and CK-p25 mice following 2-wk induction. (D) Gene ontology
analysis of total SNO-proteins identified in the cortex of control mice (dark
blue, KEGG pathways; light blue, BPs). (E) Gene ontology analysis of SNO-
proteins exclusively identified in the cortex of CK-p25 mice following 2-wk
induction (dark red, KEGG pathways; light red, BPs).
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S1). The cerebellum has an approximately equal distribution of
SNO-proteins (32%, 45%, and 23%) between control and CK-p25
mice (Fig. 2C and Dataset S1) and mirrors observations of little
change in GSNO for this brain region (Fig. 2B).
Bioinformatic Analysis of the S-Nitrosoproteome. To decipher the
possible impact of SNO-proteins on molecular and cellular sys-
tems during early neurodegeneration, we performed gene ontol-
ogy analysis of biological processes (BPs) and KEGG pathways
using the total control SNO-proteome (Fig. 2D) and the CK-p25–
specific SNO-proteome (Fig. 2E) of the cortex (34, 35). Gene
ontology clusters associated with synaptic functions were observed
for SNO-proteins in control and CK-p25 mice (BP_Synaptic
transmission and BP_Transmission of nerves impulse). The
synaptic protein synaptophysin was validated by SNOTRAP-
Western blot (Fig. S2A). Pathways associated with cognition
were identified in both control (KEGG_Long-term potentiation
and BP_Behavior) and CK-p25 mice (BP_Learning or memory).
Collectively, these data suggest that regulation of synaptic SNO-
proteins is important for normal neuronal functions associated
with learning and memory and also that the synapse is vulnerable
to aberrant SNO-signaling. NOS1, the major source of neuronal
NO, is tethered to the synapse by postsynaptic density protein 95
(PSD95; also known as DLG4) (36). Although we did not detect
SNO-PSD95 by MS, SNOTRAP-Western blot analysis shows a
strong elevation of SNO-PSD95 in CK-p25 mice (Fig. S2B), in-
dicating a susceptibility of the synapse to increased SNO during
early neurodegeneration.
SNO-proteins linked to AD were detected in the CK-p25 cortex
and not in controls, as identified by the AD KEGG pathway (Fig.
2E; GRIN2B, TAU, GSK3β, LRP1, NDUFS1, COX6B1, and
GAPDH). NOS1 is activated by N-methyl-D-aspartate receptor
(NMDAR)-mediated influx of Ca2+; subsequent S-nitrosation of
NMDAR is thought to modulate its activity. However, hyper-
excitation of NMDAR leads to excessive Ca2+ signaling and ele-
vated NO production, conditions thought to occur during
neurodegeneration. This could explain detection of SNO-GRIN2B,
a subunit of the NMDAR, in the CK-p25 mice. Amyloid activation
of the NMDAR can increase p25 production, possibly providing a
feed-forward mechanism for SNO production (18). NMDAR-
mediated p25 production and Cdk5 activation is thought to increase
glycogen synthase kinase-3β (GSK3β) and TAU (Mapt) phos-
phorylation, two key mediators of neuronal death in AD, both of
which we identified in the CK-p25 mice. Elevated SNO-GSK3β
was validated by SNOTRAP-Western blot analysis (Fig. S2A).
Cdk5 itself has been reported to be S-nitrosated, which enhances
its serine/threonine kinase activity (37). Although SNO-Cdk5 was
not detected by MS, it was elevated in CK-p25 mice (shown by
SNOTRAP-Western blot; Fig. S2B), possibly contributing to ele-
vated Cdk5 activity and acting as a feed-forward mechanism
during neurodegeneration. In addition, protein kinase C (PKC)
epsilon and gamma isoforms (Prkce and Prkcg) were S-nitrosated in
CK-p25 mice. PKC inhibits GSK3β and promotes nonamyloidogenic
processing of amyloid precursor protein (APP) through activa-
tion of α-secretase (38). S-nitrosation inhibits PKC activity (39,
40) and therefore may reduce APP processing through the
nonamyloidogenic α-secretase pathway.
Additional AD-related pathways impacted by SNO during neuro-
degeneration included apolipoprotein E (ApoE)-mediated amyloid
clearance (SNO-LRP1) and mitochondrial dysfunction (SNO-
NDUFS1 and SNO-COX6B1, which are components of CxI and
CxIV of the respiratory chain). Furthermore, Gene Ontology (GO)
analysis indicated that proteins regulating glycolysis were enriched
in the CK-p25–specific SNO-proteome (BP_Monosaccharide me-
tabolism), suggesting that elevated SNO may affect metabolic
processes during early neurodegeneration. In particular, GAPDH
was S-nitrosated in CK-p25 mice but not in control mice and was
validated by SNOTRAP-Western blot (Fig. S2A). Nuclear SNO-
GAPDH transnitrosates SIRT1, HDAC2, and DNA-PK (DNA-
dependent protein kinase, catalytic subunit), impacting metabolic
pathways, aging, and chromatin remodeling (41–43). HDAC2 was
not detected in our SNO-proteome, although we observed ele-
vated SNO-HDAC2 in CK-p25 mice by SNOTRAP-Western blot
(Fig. S2B).
Linear Motifs for S-Nitrosation. Recent studies indicate that the
specificity of SNO-Cys sites may be dependent on the spatial
proximity of charged amino acids, which are hypothesized to
CK-p25
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9
A
B
Fig. 3. SNO-site linear motif analysis indicates differential preference for
SNO-Cys sites during early neurodegeneration. (A) Linear motif generated
by pLOGO using sequences flanking SNO-Cys sites detected in control mice.
(B) Linear motif generated by pLOGO using sequences flanking SNO-Cys sites
exclusively detected in 2-wk–induced CK-p25 mice.
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Fig. 4. Pathways affected by S-nitrosation during neurodegeneration.
(A) SNO-LRP1 and SNO-PKC isoforms were identified in CK-p25 mice after
2-wk induction and have been implicated in secretase processing of APP and
amyloid clearance. (B) SNO-GSK3β and SNO-TAU were identified in CK-p25
mice after 2-wk induction and have been implicated in neurofibrillary tangle
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allow protein–protein interactions that facilitate transnitrsation
(29, 44). To elucidate common features of SNO-Cys sites, we
used the probability LOGO (pLOGO) tool to analyze flanking
sequences of SNO-Cys residues for linear motifs (45). Motif
analysis of SNO-Cys sites in control and CK-p25 mice revealed
an overrepresentation of charged flanking amino acids; however,
this was not consistent for all SNO-Cys sites (Fig. 3 A and B).
Specifically, in control mice, basic residues Arg (R) and Lys (K)
were overrepresented at the –6, –4, +1, +3, +4, and +5 positions
(Fig. 3A); these residues may be required for base-catalyzed
transnitrosation (1, 46). To test the robustness of the motif, we
performed pLOGO analysis using an independently published
SNO-proteome from brains of wild-type (C57BL/6J) mice (47)
and found an enrichment of the basic residues—Lys (K), Arg
(R), and His (H)—surrounding the SNO-Cys position (Fig. S2C,
–6, –5, –1, +3, and +4). In the CK-p25 mice, we observed Lys (K)
basic residues at the –5 and +4 positions and Glu (E) and Asp
(D) acidic residues at the –6, –4, and +5 positions (Fig. 3B). This
motif may represent charge clustering and has been previously
proposed to allow acid–base catalysis for nitrosation (base) and
denitrosation (acid) of Cys residues. Despite these observations,
many SNO-Cys sites identified in both control and CK-p25 mice
did not have charged amino acids within a proximal location of the
primary sequence. Previous studies indicate that tertiary structural
elements may be required for localizing charged residues to SNO-
Cys sites for many proteins (29, 44). Collectively, these data sug-
gest that the specificity for S-nitrosation of a subset of Cys may be
dependent on proximal charged amino acids, which possibly pro-
vide docking sites for nitrosating and denitrosating agents (29).
Conclusion
Through development of SNOTRAP, a direct SNO-tagging MS
method for detecting both small and large molecular RSNOs, we
identified an expanded endogenous SNO-proteome in the mouse
brain. We identified the hippocampus and cortex as regions
subjected to elevated levels of SNO during early stages of neu-
rodegeneration that precede the onset of detrimental behavioral
changes. The identification of SNO-PKC and SNO-LRP1 during
neurodegeneration suggests that elevated SNO may impact amy-
loid processing and clearance, thus contributing to amyloid plaque
deposition (Fig. 4A). Furthermore, detection of SNO-GSK3β and
SNO-TAU in the CK-p25 mice indicates that aberrant SNO sig-
naling may affect neurofibrillary tangle formation, another hall-
mark of AD pathology (Fig. 4B). The susceptibility of multiple
proteins to S-nitrosation during early neurodegeneration relevant
to synaptic function, metabolism, and AD pathology may drive
cellular pathologies observed at later stages, such as neuronal
loss, reduced synapse integrity, and ultimately memory impair-
ment (Fig. 4 A and B). Increased protein aggregation and cell
death linked to SNO-proteins in CK-p25 mice likely lead to ac-
tivation of inflammatory responses, an important component of
AD pathology and progression (33). The SNOTRAP strategy
provided a comprehensive assessment of S-nitrosation in the
neurodegenerating brain that can be applied to multiple cellular
and disease contexts and has therapeutic potential for biomarker
discovery and drug development.
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